ARGAMI

ARGAMI

Argatroban and alteplase in patients with Acute Myocardial Infarction. A trial comparing argatroban and heparin as adjunctive treatment to alteplase in patients with acute myocardial infarction.
Conclusion TIMI grade 2–3 flow obtained in 76% of argatroban patients (Aps) and 82% of heparin patients (HPs)—i.e., not significant; reocclusion occurred in 5.3% of APs and 0% of HPs at 24 hours.